Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02202681 |
Recruitment Status :
Recruiting
First Posted : July 29, 2014
Last Update Posted : November 7, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The study is being done to assess the tolerability and feasibility of a tethered OFDI capsule to image the duodenum.
A total of 24 subjects will be asked to swallow the tethered capsule, while they are awake and unsedated and ask for their feedback. Images will be taken using the OFDI system while the capsule travels from the esophagus into the stomach and into the duodenum.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Celiac Disease Healthy | Device: OFDI Capsule | Not Applicable |
Subjects including healthy volunteers as well as patients with Celiac disease will be recruited and asked to swallow the OFDI capsule while being awake and unsedated. The capsule is attached to a tether which allows the operator to control as well as navigate the capsule as it progresses down the esophagus, through the stomach and into the duodenum using natural propulsive force called peristalsis.
As the capsule progresses, multiple 2-dimensional cross sectional images of the duodenum are acquired. Images are analyzed at a later stage.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Pilot Study for Imaging of the Duodenum Using an OFDI Capsule |
Study Start Date : | August 2013 |
Estimated Primary Completion Date : | July 2020 |
Estimated Study Completion Date : | July 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: OFDI Capsule Imaging
Subject will swallow the OFDI Capsule and imaging will be performed using the OFDI system.
|
Device: OFDI Capsule
Imaging of the duodenum with the OFDI capsule and system |
- Tolerability of OFDI Imaging in subjects swallowing the OFDI capsule [ Time Frame: Images will be acquired during the OFDI imaging session which should on average take anywhere from 30 minutes to 2 hours. ]After participating in the study, the subject will be asked for feedback about tolerability of the procedure using a questionnaire.
- Feasibility of OFDI Imaging in subjects swallowing the OFDI capsule [ Time Frame: Images will be acquired during the OFDI imaging session which should on average take anywhere from 30 minutes to 2 hours ]An investigator will assess the quality of the recorded images and movies obtained with each exam after the imaging is completed.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Subject must be over 18 years for healthy volunteers
- Subjects must be over 16 years for patients with Celiac disease
- Subject must be able to give informed consent
Exclusion Criteria:
- Subjects with an inability to swallow pills or capsules.
- Subjects with esophageal or intestinal fistulas.
- Subjects with known esophageal or intestinal strictures resulting in a luminal diameter smaller than the diameter of the capsule.
- Subjects with a history of intestinal Crohn's disease.
- Women who are pregnant.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02202681
Contact: Anna Gao, RN | 617-643-6092 | Tearneylabtrials@partners.org | |
Contact: Anita Chung, RN | 617-724-4515 | Tearneylabtrials@partners.org |
United States, Massachusetts | |
Massachusetts General Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Contact: Anna Gao, RN 617-643-6092 Tearneylabtrials@partners.org |
Principal Investigator: | Guillermo Tearney, MD., PhD | Massachusetts General Hospital |
Responsible Party: | Guillermo Tearney, Principal Investigator, Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT02202681 |
Other Study ID Numbers: |
2013-P001405 |
First Posted: | July 29, 2014 Key Record Dates |
Last Update Posted: | November 7, 2019 |
Last Verified: | November 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Duodenum Optical Frequency Domain Imaging (OFDI) Optical Coherence Tomography Imaging Celiac Disease |
Celiac Disease Malabsorption Syndromes Intestinal Diseases |
Gastrointestinal Diseases Digestive System Diseases Metabolic Diseases |